STOCK TITAN
  1. Home
  2. News
  3. AXDX

Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first quarter financial results.

To listen by phone, dial +1.877.883.0383 and enter Elite Entry Number: 4747452. International participants may dial +1.412.902.6506. Please dial in 10–15 minutes prior to the start of the conference.

This conference call will also be webcast and can be accessed from the company's website at ir.axdx.com. A replay of the audio webcast will be available until August 6, 2021.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 10154554 until May 27, 2021.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-to-host-call-to-review-first-quarter-2021-results-301284788.html

SOURCE Accelerate Diagnostics, Inc.

Stock AXDX logo
Accelerate Diagnostics, Inc.

NASDAQ:AXDX

AXDX Rankings

#5167 Ranked by Market Cap
#4718 Ranked by Stock Gains
N/A Ranked by Dividends

AXDX Latest News

May 2, 2024
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
Mar 28, 2024
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
Mar 7, 2024
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
Jan 19, 2024
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
Jan 16, 2024
Accelerate Diagnostics Announces Launch of Proposed Public Offering

AXDX Stock Data

19.93M
13.50M
36.96%
12.06%
1.35%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
TUCSON

About AXDX

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.